Yokukansan (TJ-54) for treatment of pervasive developmental disorder not otherwise specified and Asperger’s disorder: a 12-week prospective, open-label study
Tsuyoshi Miyaoka*, Rei Wake, Motohide Furuya, Kristian Liaury, Masa Ieda, Kazunori Kawakami, Keiko Tsuchie, Takuji Inagaki and Jun Horiguchi